Share Buyback Program Announced by Becton, Dickinson and Company (NYSE:BDX) Board

Becton, Dickinson and Company (NYSE:BDX) announced that its Board of Directors has initiated a share buyback program on Thursday, November 5th, RTT News reports. The company plans to repurchase 10,000,000 outstanding shares. This repurchase authorization allows the medical instruments supplier to repurchase up to 3.6% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s board of directors believes its stock is undervalued.

Becton, Dickinson and Company Price Performance

Shares of BDX traded up $3.86 during midday trading on Thursday, hitting $213.05. 3,990,398 shares of the company traded hands, compared to its average volume of 1,721,627. The firm has a 50 day moving average of $187.69 and a 200-day moving average of $170.23. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $214.78. The stock has a market cap of $58.70 billion, a price-to-earnings ratio of 16.09, a PEG ratio of 14.10 and a beta of 0.22. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $4.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.07 by $0.08. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The firm had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.11 billion. During the same quarter last year, the business posted $3.96 earnings per share. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. On average, analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 31st. Shareholders of record on Thursday, December 10th will be issued a dividend of $1.06 per share. The ex-dividend date is Thursday, December 10th. This represents a $4.24 annualized dividend and a yield of 2.0%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 126.51%.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Wells Fargo & Company boosted their price objective on Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a research report on Friday, August 7th. UBS Group began coverage on Becton, Dickinson and Company in a research report on Tuesday, July 28th. They set a “buy” rating and a $190.00 target price for the company. Royal Bank Of Canada lifted their target price on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a research note on Thursday, August 13th. Barclays started coverage on Becton, Dickinson and Company in a research note on Wednesday, October 7th. They set an “underweight” rating and a $165.00 target price on the stock. Finally, TD Cowen boosted their price target on Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Becton, Dickinson and Company currently has an average rating of “Moderate Buy” and an average price target of $187.20.

Insiders Place Their Bets

In other news, EVP Michael Feld sold 165 shares of the stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the completion of the transaction, the executive vice president directly owned 19,720 shares in the company, valued at approximately $3,717,022.80. This represents a 0.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the firm’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. This trade represents a 3.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 6,907 shares of company stock valued at $1,269,128 in the last quarter. 0.40% of the stock is currently owned by insiders.

Key Becton, Dickinson and Company News

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: BDX reported adjusted Q4 EPS of $4.15, above analysts’ roughly $4.07 estimate, and revenue of $5.3 billion, up 5.4% year over year and ahead of expectations. For FY2026, free cash flow rose 42.5% to $2.9 billion. BD fiscal 2026 results
• Positive Sentiment: The board raised the quarterly dividend 1% to $1.06 per share, marking its 55th consecutive annual increase, and authorized an additional 10 million share repurchases. These actions may support investor returns and signal confidence in cash generation. Dividend and repurchase announcement
• Positive Sentiment: Evercore ISI raised its price target to $230 from $210, providing a favorable analyst signal. Evercore ISI price-target update
• Negative Sentiment: The main concern is FY2027 guidance: reports characterized the revenue-growth outlook as subdued and the overall outlook as largely in line with expectations. This tempered the positive reaction to the Q4 beat and has put pressure on BDX shares. Coverage of FY2027 guidance

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.